Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an...

VISTA BRINGS XO TO ASIA, STRENGTHENING FLYING SOLUTIONS AMID CONTINUED DEMAND FOR VISTAJET

VISTA BRINGS XO TO ASIA, STRENGTHENING FLYING SOLUTIONS AMID CONTINUED DEMAND FOR VISTAJET

HONG KONG and SINGAPORE, Oct. 30, 2025 /PRNewswire/ -- Vista, the world's leading private aviation group, announced its 2026 commitment and expansion plans for Asia, along with the outstanding demand for flying solutions through its leading brands...

LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload...

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus...

Hamilton Lane Expands Presence in Taiwan, Launching Evergreen Private Markets Funds

Hamilton Lane Expands Presence in Taiwan, Launching Evergreen Private Markets Funds

TAIPEI, Oct. 30, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (Nasdaq: HLNE) today announced its expansion into the Taiwan market with plans to launch evergreen investment vehicles. This strategic move into the private...

ZEISS and LG Chem join forces to strengthen the photopolymer supply chain for advanced optics

ZEISS and LG Chem join forces to strengthen the photopolymer supply chain for advanced optics

ZEISS and LG Chem established a strategic framework for industrial-scale photopolymer film supply in advanced optics. Partners co-develop photopolymer solutions for next-generation automotive holographic windshield displays, aiming for OEM...

ATMOCE Enters Australia with Advanced Solar Power Generator Solutions

ATMOCE Enters Australia with Advanced Solar Power Generator Solutions

MELBOURNE, Australia, Oct. 30, 2025 /PRNewswire/ -- Atmoce, a global energy technology company headquartered in Germany with operations in over 20 countries, officially announced its Australian market entry at All-Energy Melbourne 2025. With proven...

MGM China Reports 2025 Third-Quarter Results

MGM China Reports 2025 Third-Quarter Results

Record Third Quarter Adjusted EBITDA Posted 20% Year-on-Year Growth HONG KONG, Oct. 30, 2025 /PRNewswire/ -- MGM China Holdings Limited ("MGM China" or the "Company"; SEHK Stock Code: 2282) today announced the selected unaudited financial data of...

Webull to Release Third Quarter 2025 Results on November 20, 2025

Webull to Release Third Quarter 2025 Results on November 20, 2025

ST. PETERSBURG, Fla., Oct. 30, 2025 /PRNewswire/ -- Webull Corporation (NASDAQ: BULL) today announced that it will release its third quarter 2025 earnings results after market close on November 20, 2025. On that day, the management team will host a...

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong...

  • 1
  • ...
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • ...
  • 205
  • menu
    menu